(BUSINESS WIRE)–Jan. 9, 2015– Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), leaders in RNA-targeted therapeutics, announced today they have formed a new agreement, extending their existing strategic partnership – formed originally in 2004 – to lead the development and commercialization of RNA therapeutics. This new agreement includes a cross-license of intellectual property (IP) on four disease targets, providing e… Read more
Shares of Isis Pharmaceuticals closed yesterday at $71.93 . ISIS has a 1-year high of $72 and a 1-year low of $22.25. The stock’s 50-day moving average is $58.61 and it’s 200-day moving average is $43.00.
One research analyst has assigned a Hold rating and 5 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is 71.93$ which is -11.0% under where the stock closed yesterday.
Isis Pharmaceuticals is engaged in antisense drug discovery and development, exploiting a novel drug discovery platform it created to generate a broad pipeline of first-in-class drugs.